Literature DB >> 18212788

Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine.

Tanya C Warwick1, Venkata Moningi, Prasuna Jami, Kristy Lucas, Ogochukwu Molokwu, Shalini Moningi.   

Abstract

BACKGROUND: A 78-year-old man with a 22-year history of schizoaffective disorder and a 5-year history of dementia presented to the emergency department with a 5-day history of fatigue, progressive weakness, confusion and lethargy, and a 1-day history of severe muscle stiffness. For the past 10 years the patient had been treated with olanzapine for an unspecified psychiatric illness, without adverse effects. One week before presentation the patient was started on donepezil to treat mild dementia. INVESTIGATIONS: Physical examination, serum and urine laboratory evaluation, lumbar puncture, brain CT scan, brain MRI, electroencephalogram, chest X-ray, and electrocardiogram. DIAGNOSIS: A variant of neuroleptic malignant syndrome secondary to drug interaction. MANAGEMENT: Discontinuation of donepezil and olanzapine, aggressive intravenous hydration, intravenous dantrolene, and bromocriptine via a nasogastric tube. The patient was also administered intravenous antibiotics for aspiration pneumonia, and carbidopa-levodopa for residual parkinsonian features.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18212788     DOI: 10.1038/ncpneuro0728

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  3 in total

1.  A case report of neuroleptic malignant syndrome.

Authors:  Shankar Srinivas Kuchibatla; Sofia Akram Cheema; Kripa S Chakravarthy; Hany George El Sayeh
Journal:  BMJ Case Rep       Date:  2009-05-20

Review 2.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  An atypical case of serotonin syndrome with normal dose of selective serotonin inhibitors: A case report.

Authors:  Yun Liu; Hailong Yang; Fei He; Peng Xu; Hanwen Tong; Yao Liu; Jie Ni; Qiulin Zhang; Jun Wang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.